当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2017年第3期
编号:13011286
造影剂肾病发病机制、危险因素及防治的研究进展(5)
http://www.100md.com 2017年1月25日 《中国医药导报》 2017年第3期
     [21] 詹碧鸣,潘雄,孙文华,等.前列地尔对冠状动脉造影患者对比剂肾病预防用的Meta分析[J].循证医学,2015,15(3):161-167.

    [22] Barbieri L,Verdoia M,Schaffer A,et al. The role of statins in the prevention of contrast induced nephropathy:a meta-analysis of 8 randomized trials [J]. J Thromb Thrombolysis,2014,38(4):493-502.

    [23] 李顺辉,刘丽赟,童一帆,等.瑞舒伐他汀钙在预防急性冠脉综合征介入术影剂肾病中的应用效果[J].中国当代医药,2015,22(32):144-147.

    [24] Wong GT,Lee EY,Irwin M G. Contrast induced nephropathy in vascular surgery [J]. Br J Anaesth,2016,117(suppl 2):ii63.

    [25] Cruz DN,Perazella MA,Bellomo R,et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy:a systematic review [J]. Am J Kidney Dis,2006,48(3):361-371.

    [26] Fulvio S,Andy A,Becker C R,et al. Strategies to reduce the risk of contrast-induced nephropathy [J]. Am J Cardiol,2006,98(6):59-77.

    [27] Cho A,Lee JE,Yoon J Y,et al. Effect of an electronic alert on risk of contrast-induced acute kidney injury in hospitalized patients undergoing computed tomography [J]. Am J Kidney Dis,2012,60(1):74-81.

    (收稿日期:2016-10-10 本文編辑:李岳泽), http://www.100md.com(彭佳 谭波宇 宁宁)
上一页1 2 3 4 5